Navigation Links
Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Date:3/3/2008

the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-104, the development of the Company's product candidates, projected clinical trial enrollment and data reporting timelines, and safety of the Company's products and technologies. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Mass. , Sept. 3, 2015 ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that its President and Chief Executive Officer, ... the 2015 Wells Fargo Healthcare Conference at 8:50 a.m. ... held Sept. 9-10, 2015 at The Hyatt Regency, ...
(Date:9/3/2015)... PLEASANTON, Calif. , Sept. 3, 2015 /PRNewswire/ ... detailed in a white paper released by ... the Agency for Healthcare Research & Quality (AHRQ), ... an estimated $9.1-$11.6 billion annually . In addition ... result in litigation, government penalties, and negatively impact ...
(Date:9/3/2015)... Sept. 3, 2015  Omeros Corporation (NASDAQ: OMER ... lawsuits against Par Pharmaceutical, Inc. and its subsidiary, Par ... Court for the District of New Jersey ... the District of Delaware . The ... infringement of three Omeros patents, U.S. Patent Nos. 8,173,707, ...
Breaking Medicine Technology:HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4
... Reveals Shift in Prescribing Patterns As More MDs ... of Cholesterol-Reducing Drug, NEW YORK, Feb. 7 ... trial results on January 14, 2008,physicians are less concerned ... results than they were initially, according to a pivotal ...
... SAN FRANCISCO, Calif., Feb. 7 Researchers ... annual meeting,showing that training on the Posit ... cancer patients with "chemobrain". "Chemobrain",is a condition ... It affects quality of life by impairing ...
Cached Medicine Technology:Physicians Reconsider Implications of Enhance Trial 2Neuroscientists Offer Hope for Breast Cancer Patients Suffering From 'Chemobrain' 2
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional ... her debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , ... guide to overcoming life’s obstacles by taking full responsibility for one’s life shares ...
(Date:9/3/2015)... ... 03, 2015 , ... Girl’s Night Out to benefit Core Compassion Project will ... Kate Road in Monroe, North Carolina. The event food will be provided ... Kate Clyde’s offers off-premise catering and event services from casual to elegant. They are ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... included Intellicure, Inc., in its Annual Inc. 5000 list of fastest-growing private ... that "only a tiny fraction of the nation's companies have demonstrated such remarkably ...
(Date:9/3/2015)... ... September 03, 2015 , ... B. ... has been retained to lead a national chief executive officer recruitment ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse Advisor article ... help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for ... by HPV infections, which have a high rate of success in treatment and elimination ...
Breaking Medicine News(10 mins):Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3
... an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University,s ... L803-MTS, to treat a number of central nervous system ... shows promise against Parkinson,s, Huntington,s and diabetes. ... GSK3 protein, which plays a causative role in insulin ...
... a family involved in several human diseases is crucial ... research has found, suggesting that the protein might play ... channel, a passageway that allows negatively-charged chloride ions to ... insulin of normal mice, according to research published this ...
... , MONDAY, Oct. 26 (HealthDay News) -- Black women ... a breast abnormality, a U.S. study has found. , ... is detected at a later stage, which may reduce ... at the University of South Carolina in Columbia analyzed ...
... heart from complications of extra weight, study finds, , ... that you can be both fat and fit, new ... have some risk factors for heart disease. , ... and major league baseball players, researchers found that football ...
... ... ... 26, 2009 -- Safety Management Services, Inc. (SMS, Inc.), a Chicago-based healthcare ... examination. Developed in support of the Certified Healthcare Emergency Professional (CHEP) certification , ...
... R.I., Oct. 26 According to The ... are used in the U.S. each year, and only roughly ... encourage shoppers to cut down on the use of single-use ... called GreenBagTag which rewards members of the company,s ...
Cached Medicine News:Health News:A nervous system drug-by-design 2Health News:Protein critical for insulin secretion may be contributor to diabetes 2Health News:Protein critical for insulin secretion may be contributor to diabetes 3Health News:Breast Abnormality Follow-Up Often Later in Black Women 2Health News:Big, Beefy Football Players May Face Heart Problems Later 2Health News:Big, Beefy Football Players May Face Heart Problems Later 3Health News:Safety Management Services, Inc. Develops New Regional Preparation Course And Exam For CHEP Certification 2Health News:Safety Management Services, Inc. Develops New Regional Preparation Course And Exam For CHEP Certification 3Health News:CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags 2Health News:CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: